Skip to main content

Spineway : a week dedicated to medical excellence with more than 20 surgeons trained

Press release        

Ecully, November 14, 2024 – 6 p.m.

Spineway: a week dedicated to medical excellence with more than 20 surgeons trained

The Spineway Group, a , specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international surgeons in the use of the Group’s ESP cervical and lumbar prostheses. These events also enabled the Group’s distributors to provide ongoing training and support for their users.
           

The week began with a Costa Rican surgeon being trained in the operating room by Pr. Lazennec (Hôpital de la Pitié-Salpêtrière, AP-HP Paris) on cervical prosthesis (CP-ESP) and lumbar prosthesis (LP-ESP).

This was followed by a training session with two Indonesian surgeons led by Pr. Rousseau (Hôpital Bichat-Beaujon – AP-HP Paris), who focused on the LP-ESP lumbar prosthesis. At the end of the day, Mexican and Costa Rican practitioners had the opportunity to discuss their experiences with disc prostheses with Dr. Thierry Marnay during a round table in Nîmes.

The Mexican practitioners continued their training by participating in several procedures with the LP-ESP lumbar disc prosthesis. These sessions were led by Dr. Guillaume Gras-Combe (CHU de Nîmes-Pôle Neurosciences) and Dr. Jean-Patrick Rakover (Clinique du Pré, Le Mans).

The week ended with a training session on anatomical specimens at IRCAD Strasbourg for all the practitioners trained in the operating room during the week. They were joined by five Spanish and three Portuguese surgeons. Led by the experts Pr. Rousseau, Dr. Gras-Combe, Dr. Javier Giner (Instituto Clavel, Madrid) and Dr. Eduardo Espinosa (Neurocirugía Barcelona), the training included theoretical and practical sessions covering the characteristics, indications and surgical approaches for the placement of ESP disc prostheses.

Spineway’s teams, including Yiyi Li (MEA & Asia-Pacific Sales Manager), Lorenzo Tamas (Latin American Sales Manager), Inès Khaoua (Europe Sales Manager), Mélody Ourdouillié (Medical Education Events Manager) and Loïc Aden (ESP Product Manager), were on hand to provide optimal support.

These exchanges between surgeons illustrate Spineway’s commitment to supporting health professionals in their training, ensuring mastery of advanced technologies in the field of spinal implants and supporting the development of its international network. Spineway thus confirms its aim of becoming a major player in less invasive spine treatments in Europe, Latin America and Asia.

Next events:

December 5, 2024 – 6 p.m. CET – Webinar – Business update
Register here

January 22, 2025 – Full-year 2024 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.
ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY

Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060

 

AELIUM

Investor relations

Solène Kennis

spineway@aelium.fr

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.